We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
+11.13%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.94B
AUM Growth
-$123M
Cap. Flow
-$193M
Cap. Flow %
-4.9%
Top 10 Hldgs %
32.83%
Holding
121
New
17
Increased
40
Reduced
11
Closed
7

Top Buys

Rank Stock Value
1
SGRY icon
Surgery Partners
SGRY
+$30.8M
2
LLY icon
Eli Lilly
LLY
+$24M
3
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$20.7M
4
PHVS icon
Pharvaris
PHVS
+$20M
5
OSCR icon
Oscar Health
OSCR
+$18.8M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$163M
2
CERE
Cerevel Therapeutics Holdings, Inc. Common Stock
CERE
+$89.3M
3
HUM icon
Humana
HUM
+$61.6M
4
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$49.1M
5
BPMC
Blueprint Medicines
BPMC
+$32.9M

Sector Composition

Rank Sector Weight
1 Healthcare 96.7%
2 Consumer Staples 1.95%
3 Industrials 0.94%
4 Financials 0.06%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
BPMC
1
DELISTED
Blueprint Medicines
BPMC
$237M 6.02%
2,498,448
-383,119
-13% -$32.9M
IMCR icon
2
Immunocore
IMCR
$1.72B
$154M 3.91%
2,367,816
-293,691
-11% -$20.2M
NBIX icon
3
Neurocrine Biosciences
NBIX
$16.8B
$145M 3.69%
1,054,900
-141,100
-12% -$19.3M
EVH icon
4
Evolent Health
EVH
$348M
$131M 3.32%
3,987,500
+27,500
+0.7% +$878K
ISRG icon
5
Intuitive Surgical
ISRG
$127B
$119M 3.02%
298,500
– –
UNH icon
6
UnitedHealth
UNH
$376B
$114M 2.89%
230,000
– –
PEN icon
7
Penumbra
PEN
$12.7B
$113M 2.86%
505,000
-32,500
-6% -$8.03M
IDXX icon
8
Idexx Laboratories
IDXX
$44.1B
$96.8M 2.46%
179,250
– –
ACHC icon
9
Acadia Healthcare
ACHC
$2.76B
$93.3M 2.37%
1,177,500
+104,000
+10% +$8.5M
ARGX icon
10
argenx
ARGX
$53.4B
$90.3M 2.29%
229,250
– –
BSX icon
11
Boston Scientific
BSX
$69.5B
$84.4M 2.14%
1,232,500
– –
RARE icon
12
Ultragenyx Pharmaceutical
RARE
$2.45B
$82.9M 2.1%
1,774,938
+20,900
+1% +$986K
DXCM icon
13
DexCom
DXCM
$31.5B
$82.8M 2.1%
596,750
+750
+0.1% +$94.3K
LLY icon
14
Eli Lilly
LLY
$1.02T
$80.3M 2.04%
103,250
+33,750
+49% +$24M
FRPT icon
15
Freshpet
FRPT
$2.93B
$76.8M 1.95%
662,500
– –
MDGL icon
16
Madrigal Pharmaceuticals
MDGL
$10.8B
$76.4M 1.94%
285,931
+87,762
+44% +$20.7M
EXAS
17
DELISTED
Exact Sciences
EXAS
$73.2M 1.86%
1,059,750
+40,250
+4% +$2.55M
ALGN icon
18
Align Technology
ALGN
$12.1B
$72.1M 1.83%
220,000
– –
RYTM icon
19
Rhythm Pharmaceuticals
RYTM
$6.81B
$66M 1.68%
1,522,893
– –
EW icon
20
Edwards Lifesciences
EW
$49.6B
$61.9M 1.57%
647,300
– –
KYMR icon
21
Kymera Therapeutics
KYMR
$8.51B
$61.2M 1.55%
1,522,238
– –
CLDX icon
22
Celldex Therapeutics
CLDX
$2.99B
$57.6M 1.46%
1,372,185
+402,539
+42% +$16.5M
PHR icon
23
Phreesia
PHR
$663M
$56.6M 1.44%
2,365,000
+158,300
+7% +$3.93M
PODD icon
24
Insulet
PODD
$11.5B
$54.8M 1.39%
320,000
-111,750
-26% -$20.8M
WST icon
25
West Pharmaceutical
WST
$24B
$54.3M 1.38%
137,250
– –
1
2 3 4 5

Similar funds

AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
SGI
Summit Global Investments Bountiful, Utah $1.69B AUM 12.13% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
FDP
Financiere des Professionnels Montreal, Quebec, Canada $1.71B AUM 21.77% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return

Rock Springs Capital Management's Q1 2024 Portfolio in Review

As of Q1 2024, Rock Springs Capital Management held 121 positions worth $3.94B, down 3% from $4.06B the previous quarter. Its ten largest holdings account for 33% of the portfolio.

Rock Springs Capital Management withdrew a net $193M in Q1 2024, closing 7 positions and reducing 11 holdings. Its most notable exit was Karuna Therapeutics, Inc. Common Stock, an estimated $163M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 97% of assets, down from 97% a quarter earlier, followed by Consumer Staples and Industrials.

Against the trend, Rock Springs Capital Management opened a new position in Surgery Partners worth $29.4M.

  • Rock Springs Capital Management's largest Q1 2024 buy was Surgery Partners: 985,000 shares worth $29.4M.
  • Rock Springs Capital Management added most to Eli Lilly in Q1 2024, an estimated $24M increase.
  • Rock Springs Capital Management's biggest Q1 2024 reduction was Cerevel Therapeutics Holdings, Inc. Common Stock, cutting an estimated $89.3M.
  • Rock Springs Capital Management fully exited Karuna Therapeutics, Inc. Common Stock in Q1 2024, selling an estimated $163M.
  • Rock Springs Capital Management's ten largest holdings make up 33% of its $3.94B portfolio in Q1 2024.
  • Rock Springs Capital Management opened 17 new positions and closed 7 in Q1 2024.
  • Rock Springs Capital Management's portfolio value fell 3% quarter-over-quarter to $3.94B.

Based on Rock Springs Capital Management's 13F filing for Q1 2024, filed 15 May 2024.